PCM
IDYA icon

Prelude Capital Management’s IDEAYA Biosciences IDYA Stock Holding History

Prelude Capital Management’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,323
Closed -$219K – 1385
2025
Q4 		$219K Buy
+6,323
New +$202K 0.02% 1004
2020
Q4 		– Sell
-200
Closed -$3K – 1598
2020
Q3 		$3K Buy
+200
New +$2.48K ﹤0.01% 1628
2020
Q1 		– Sell
-1,674
Closed -$13K – 1703
2019
Q4 		$13K Buy
+1,674
New +$11.9K ﹤0.01% 1666

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Prelude Capital Management's IDYA Position: Q1 2026 in Review

Prelude Capital Management sold out of IDEAYA Biosciences (IDYA) in Q1 2026, closing a stake of 6,323 shares — an estimated $219K sold.

Prelude Capital Management first reported a position in IDYA in Q4 2019 and held it in 3 quarters. The position peaked at $219K in Q4 2025. 254 funds tracked by Wall St. Rank hold IDYA as of Q1 2026.

  • Prelude Capital Management reported no remaining IDEAYA Biosciences position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 6,323 IDEAYA Biosciences shares in Q1 2026, an estimated $219K.
  • Prelude Capital Management first reported a position in IDEAYA Biosciences in Q4 2019 and held it in 3 quarters.
  • Prelude Capital Management's IDEAYA Biosciences position peaked at $219K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.